Pharma BD Deal Intelligence
The $5.6B ($4.4B) acquisition gave UCB the neurology pipeline that became its long-term core—lacosamide (Vimpat) grew into a genuine blockbuster and integration synergies beat target ahead of schedule. Though a 2008 Neupro patch recall and two years of profit collapse (down 60% and 74%) proved the integration was far from clean.
The deal that built modern UCB neurology — Vimpat became a genuine blockbuster, but a 2008 product recall and two years of profit collapse show it was far from a clean win
Full analysis, sources & comparables →Deal positions UCB as a focused mid-cap CNS specialist; family-controlled Schwarz (~60% holding) backed the friendly takeover, bringing late-stage Neupro and…
UCB to acquire Schwarz Pharma at €91.1/share (€50 cash + 0.8735 UCB share), valuing Schwarz at €4.4B; expected synergies >€300M annually after 3 years;…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
CNS (Parkinson's, epilepsy, RLS); EUR 4.4B; lacosamide pipeline
The deal that built modern UCB neurology — Vimpat became a genuine blockbuster, but a 2008 product recall and two years of profit collapse show it was far from a clean win
Assessment window: 15yr post-close.
90K US cases/yr · $82.2B US PD direct+indirect cost 2024
Parkinson's disease is a progressive neurodegenerative disorder driven by dopaminergic neuron loss in the substantia nigra, producing tremor, rigidity, bradykinesia, and postural instability. Therapy is symptomatic, anchored on levodopa with adjunctive dopamine agonists, MAO-B inhibitors, and COMT inhibitors; transdermal delivery of dopamine agonists addressed compliance and 24-hour coverage gaps.
The mid-2000s Parkinson's market was anchored by oral dopamine agonists Mirapex (pramipexole, BI/Pfizer) and Requip (ropinirole, GSK), MAO-B inhibitor Eldepryl (selegiline), COMT inhibitor Comtan (entacapone, Novartis), and the levodopa/carbidopa backbone (Sinemet). Schwarz Pharma's Neupro (rotigotine) launched in 2007 as the first transdermal dopamine agonist patch, offering continuous 24-hour delivery. The asset suffered a major US setback when Schwarz/UCB recalled it in 2008 over crystallization issues, returning to the US market in 2012. Despite the recall, Neupro became a meaningful franchise globally for restless legs syndrome and Parkinson's. The UCB-Schwarz deal therefore underwrote a CNS-portfolio bet — Neupro + lacosamide + UCB's Keppra/Cimzia — that Credit Suisse and others viewed as strategically coherent given UCB's neurology expertise.
$1.5B Lacosamide projected peak sales (Credit Suisse)
Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures, with roughly one-third of patients drug-resistant on standard antiepileptic regimens. Adjunctive novel-mechanism agents are the principal innovation lane; UCB's Keppra (levetiracetam) and Schwarz's lacosamide (Vimpat) brought differentiated MOAs to partial-onset seizures.
In 2006 the epilepsy market was led by UCB's own Keppra (levetiracetam, ~€1B sales), Pfizer's Lyrica (pregabalin) and Neurontin (gabapentin), GSK's Lamictal (lamotrigine), and J&J/Janssen's Topamax (topiramate). Schwarz Pharma's late-stage candidate lacosamide (later Vimpat) — a sodium-channel slow-inactivation modulator — was the strategic centerpiece. Credit Suisse analyst Ravi Mehrotra projected UCB's neurology franchise expertise could 'turn lacosamide from a product with peak sales of around €700M to a $1.5B product'. The deal also delivered Neupro (rotigotine) for Parkinson's and restless legs syndrome, plus Cimzia upside on UCB's side. Combined R&D budget of €770M and €300M+ annual synergies after three years framed the integration. Subsequent generic erosion of Keppra (2008) and Vimpat's eventual ~$1B+ peak validated the thesis directionally; Vimpat lost US exclusivity in 2022.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB SA / Schwarz Pharma AG (this deal) | 2006 | $5.6B | 80 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals